Gastrointestinal Cancer

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Olaparib has received an orphan drug designation in Japan for the maintenance treatment of germline BRCA-mutated curatively unresectable pancreatic cancer.

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Ghassan K. Abou-Alfa, MD, provides perspective on the accelerated approval of nivolumab and ipilimumab in advanced hepatocellular carcinoma.

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Richard S. Finn, MD, the burst of available treatment options, the ongoing hunt for actionable biomarkers, and the importance of multidisciplinary care in hepatocellular carcinoma.

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.

Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.